WEST DES MOINES, IA--(NewMediaWire - Mar 16, 2016) -
Spotlight Innovation Inc. (OTCQB: STLT)
has entered into a Research Agreement with the University of
Alabama at Birmingham (UAB) to conduct studies to validate the
efficacy of Spotlight Innovation's Immunoplex™ immunotherapy
platform technology for metastatic breast cancer in mouse models.
These pre-clinical studies are anticipated to take approximately
six months and are intended to validate significant and highly
favorable prior test data. The data will be submitted as part of an
Investigational New Drug (IND) filing with the U.S. Food and Drug
Administration. Lyse A. Norian, PhD, is the Principal Investigator.
Dr. Norian conducted the original studies during her tenure at the
University of Iowa.
The study protocol includes the examination of primary tumor
growth in mice, the examination of metastatic tumor growth in mice
with resected primary tumors, and analyses of tumor-infiltrating
and systemic leukocytes in tumor-bearing mice.
Tony Vanden Bush, PhD, co-inventor of the Immunoplex™
immunotherapy platform and Spotlight Innovation's Manager of
Product Development, said, "We are looking forward to validating
our previous results. This is a key step in the submittal of our
IND and the commencement of human clinical trials."
Cris Grunewald, President and Chief Executive Officer of
Spotlight Innovation, said, "We are pleased to be cooperating, once
again, with Dr. Norian in her new role at UAB, and look forward to
advancing our personalized cancer tumor therapy technology to the
human testing phase."
About Immunoplex™
Immunoplex™ is a vaccine platform technology that utilizes a
"universal" antibody, in conjunction with a proprietary epitope
"adapter," that binds to targeted antigens to treat or prevent
specific diseases. Applications for the technology are solid
cancerous tumors (a broad range of cancer indications) and a
virtually unlimited number of viral and bacterial infections. This
technology has the potential to create numerous "immune complex
vaccines" for a wide range of indications. Because the Immunoplex™
therapy utilizes cancer cells from a patient's own tumor, it is
a truly personalized cancer treatment.
About Spotlight Innovation Inc.
Spotlight Innovation Inc. (OTCQB: STLT)
identifies and acquires rights to innovative and proprietary
platform technology candidates with a focus on cancer drugs and
related treatment therapies, solutions for infectious disease, and
other specialty and unique opportunities. Access to platform
technology candidates is accomplished via our extensive
relationships with many leading academic institutions and other
sources. We provide value-added development capability and funding
in order to accelerate development progress. When commercially
significant benchmarks have been achieved, we will partner with
proven market leaders via sale, out-license or strategic alliance.
For more information, visit www.spotlightinnovation.com or follow us
on www.twitter.com/spotlightinno.
Forward Looking Statements
Statements in this press release that are not purely historical
are forward-looking statements. Forward-looking statements herein
include statements regarding the results of the pre-clinical
studies, the ability of UAB to validate these results, and
Spotlight Innovation's efforts to develop and commercialize its
various technologies. Actual outcomes and actual results could
differ materially from those in such forward-looking statements.
Factors that could cause actual results to differ materially
include risks and uncertainties such as the inability to replicate
conditions under which the original results were obtained, the
inability to finance the planned development of the technologies,
the inability to hire appropriate staff to develop the
technologies, unforeseen technical difficulties in developing the
technologies, the inability to obtain regulatory approval for human
use, competitors' therapies proving to be more effective, cheaper
or otherwise more preferable, the inability to market a product,
all of which could, among other things, delay or prevent product
release, as well as other factors expressed from time to time in
Spotlight Innovation's periodic filings with the Securities and
Exchange Commission (the "SEC"). As a result, this press release
should be read in conjunction with Spotlight Innovation's periodic
filings with the SEC. The forward-looking statements contained
herein are made only as of the date of this press release and
Spotlight Innovation undertakes no obligation to publicly update
such forward-looking statements to reflect subsequent events or
circumstances.